Figure 1 Flortaucipir PET MUBADA/PERSI SUVr at baseline, 9 and 18 months for individual subjects. Each subject is ... Figure 1 Flortaucipir PET MUBADA/PERSI.

Slides:

Advertisements

Similar presentations

Table 1 Patient characteristics of attendees of the influenza vaccination, irrespective of AF status From: Yield of screening for atrial fibrillation in.

Advertisements

Figure 5: Three-dimensional reconstruction of the CT scan showing the trapped air in the head and neck region. From: Distinct subcutaneous emphysema following.

From: Learning by Working in Big Cities

Fig. 1 Nodes in a conceptual knowledge graph

Figure 1: Pneumomediastinum and subcutaneous emphysema as indicated by the arrows. From: Pneumomediastinum and subcutaneous emphysema after successful.

From: Detection of Bacteriuria by Canine Olfaction

Figure 1: (A, frontal) and (B, lateral) Final result, 4 months post-operative, after right breast reconstruction using combined TRAM flap and LDMF. From:

Figure 3: Full-body skeletal scintigraphy.

Figure 1. The flow chart illustrates the construction process of anti-CRISPRdb, and the information that users can obtain from anti-CRISPRdb. From: Anti-CRISPRdb:

Figure 1: Necrobiosis lipoidica: Yellow-brown skin lesions with indurated borders located on both lower legs. Figure 1: Necrobiosis lipoidica: Yellow-brown.

Figure 1. Circular taxonomy tree based on the species that were sequenced in our study. Unless provided in the caption above, the following copyright applies.

ADAb: anti-drug antibody.

Figure 1. Overview of the workflow of NetworkAnalyst 3.0.

FIGURE 1 Kidney biopsies of Patients 1 and 2

Figure 1 Hazard ratios as a function of annual mean PM2

Figure 1 Schematic representation of the extreme SVD design in the 3C-Dijon study. Unless provided in the caption above, the following copyright applies.

Figure 1: Axial T2 W images of penis showed a well-defined septated area of 2 cm in the posterior aspect of ... Figure 1: Axial T2 W images.

FIGURE 1 Histological diagnoses divided into 8-year time frames (n = 1208). Unless provided in the caption above, the following copyright applies to the.

FIGURE 1 The effect of daprodustat on hemoglobin (Hgb) levels

FIGURE 2 Responses to the question: regarding vasoactive drugs, does your centre use the following frequently, rarely ... FIGURE 2 Responses to the question:

FIGURE 1 Maternal (A) urinary aldosterone; (B) plasma active renin; (C) urinary AGT concentrations; and (D) plasma AGT ... FIGURE 1 Maternal (A) urinary.

FIGURE 1 Flow chart of patient enrollment and exclusion

Figure 1. Ratios of observed to expected numbers of exon boundaries aligning to boundaries of domain and disorder ... Figure 1. Ratios of observed to expected.

Fig. 1 Kaplan-Meier plot of cumulative incidence of cancer onset following dermatomyositis diagnosis stratified ... Anti-TIF1-Ab: anti-transcriptional.

Figure 1 The occurrence of maternal cardiovascular events for the different diagnosis groups. AOP, aortic pathology; ... Figure 1 The occurrence of maternal.

Figure 1 KCTD16 antibodies are associated with an underlying tumour

Fig. 1 Mean change from baseline in ANC ± s. e

Point estimates with ... Point estimates with 95% CI. HR: hip replacement; KR: knee replacement. Unless provided in the caption above, the following copyright.

FIGURE 1 Participant flow diagram. Exercise Counseling Clinic (ECC).

Graph 1. The number of homicide cases per year discussing neuro-evidence. Unless provided in the caption above, the following copyright applies to the.

Figure 1. Analysis of human TRIM5α protein with Blast-Search and PhyML+SMS ‘One click’ workflow. (A) NGPhylogeny.fr ... Figure 1. Analysis of human TRIM5α.

Figure 2. Natural history of chlamydia transmission, with arrows showing the transitions between health states. Figure 2. Natural history of chlamydia.

Figure 1. Mean concentration–time profiles of ascending doses of ivermectin in (a) PSAC and (b) SAC. Weight-dependent ... Figure 1. Mean concentration–time.

Figure 1 Nelson-Aalen estimates of the cumulative incidence rates for patients on versus off IST. ON = optic neuritis; ... Figure 1 Nelson-Aalen estimates.

FIGURE 1 Malta: a plate-style food guide

Figure 1. A, Crude incidence rates per 100 person-years of follow-up and 95% confidence intervals for each solid organ ... Figure 1. A, Crude incidence.

FIGURE 1 Study consort diagram

Fig. 2 Case 2. Levels of serum creatinine and anti-GBM antibodies before and during treatment with cyclophosphamide, ... Fig. 2 Case 2. Levels of serum.

Figure 1. Illustration of DGR systems and their prediction using myDGR

Figure 1. The pipeline of Aggrescan3D 2.0 server.

FIGURE 1 Food groups consumed (mean, g/d) among US infants and young children by age group and tertile of mean ... FIGURE 1 Food groups consumed (mean,

Figure 1 Study flowchart and patient flow

Figure 1. Prediction result for birch pollen allergen Bet v 1 (PDB: 1bv1), as obtained by comparison to the cherry ... Figure 1. Prediction result for.

Figure 1. Using Voronoi tessellation to define contacts

Figure 1. PaintOmics 3 workflow diagram

Figure 1. Schematic diagram of solar energy and coal-fired power generation system. Unless provided in the caption above, the following copyright applies.

Figure 1. Uncertainty reduction, value creation, and appropriation in two case studies. Unless provided in the caption above, the following copyright applies.

Figure 1 Ratio of the geometric mean concentration of hsTnT (A) and sST2 (B) at baseline (BL) and each subsequent ... Figure 1 Ratio of the geometric mean.

Figure 1 Visuomotor grip force-tracking set-up and conditions

Figure 1. Time to clinical stability (a) and time to defervescence (b) in patients with pneumococcal pneumonia. ... Figure 1. Time to clinical stability.

Figure 1. MERMAID web server interface (Start page, Parameter page): MERMAID provides two ways to submit a protein ... Figure 1. MERMAID web server interface.

Figure 1. Yvis platform overview

Figure 1. The framework of NetGO with seven steps

Figure 1. Workflow of the HawkDock server that is divided into three major steps: (i) input of unbound or bound protein ... Figure 1. Workflow of the HawkDock.

Figure 1 Patient disposition

Figure 1. Overview of BEECH study exploratory analysis

Fig. 1. —Synteny analysis of melon chromosome 1 (brown) and cucumber chromosome 7 (green) based on melon-cucumber ... Fig. 1. —Synteny analysis of melon.

Figure 1. Trial profile. (A) Part A and (B) part B

Figure 1 Design of trials included in individual patient data meta-analysis. Unless provided in the caption above, the following copyright applies to the.

Figure 1. Scheme of a phosphorothioated-terminal hairpin formation and self-priming extension (PS-THSP) for selection ... Figure 1. Scheme of a phosphorothioated-terminal.

Figure 1 Correlation between en face Oil-Red O staining and aortic root lesion size vs. plasma cholesterol and ... Figure 1 Correlation between en face.

Figure 1. The proportion of CSBM responders over the 2-week treatment period (A), the proportion of SBM responders by ... Figure 1. The proportion of CSBM.

Figure 1 Genetic results. No case had more than one diagnostic result

Figure 1. (A) Baseline contrast-enhanced CT scan of melanoma patient presenting with metastases in the liver and lymph ... Figure 1. (A) Baseline contrast-enhanced.

Figure 1. Prevalence of parasitic infection and anemia among the children. Unless provided in the caption above, the following copyright applies to the.

Figure 1. GWAS Catalog associations for coronary artery disease plotted across all chromosomes. Associations added ... Figure 1. GWAS Catalog associations.

Source:Zimnisky (2014). Source:Zimnisky (2014).

Figure 1 Mechanisms of mitral regurgitation.

Fig. 2. Genetic differentiation among populations and individuals

Figure 1. Hepatitis C screening and diagnostic algorithm at the MSF clinic, Karachi, Pakistan, March 2016–September ... Figure 1. Hepatitis C screening.

Presentation transcript:

Figure 1 Flortaucipir PET MUBADA/PERSI SUVr at baseline, 9 and 18 months for individual subjects. Each subject is ... Figure 1 Flortaucipir PET MUBADA/PERSI SUVr at baseline, 9 and 18 months for individual subjects. Each subject is plotted by age at baseline and follow-up time points on the x-axis. Symbols reflect clinical diagnosis [cognitively normal (CN), MCI, Alzheimer’s disease (AD)]. Subjects shown in red were amyloid-β+ and subjects in blue amyloid-β− by florbetapir amyloid PET scan. For amyloid-β+ subjects baseline SUVr was inversely related to age (r = −0.57, P ≤ 0.0001). Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) (2019). Published by Oxford University Press on behalf of the Guarantors of Brain.This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com Brain, awz090, https://doi.org/10.1093/brain/awz090 The content of this slide may be subject to copyright: please see the slide notes for details.

Figure 2 Correlation of baseline flortaucipir PET MUBADA SUVr (A) or age at baseline (B) with change from baseline ... Figure 2 Correlation of baseline flortaucipir PET MUBADA SUVr (A) or age at baseline (B) with change from baseline flortaucipir PET MUBADA SUVr. Individual subjects are shown with symbols reflecting clinical diagnosis [cognitively normal (CN), MCI, Alzheimer’s disease (AD)]. Subjects shown in red were amyloid-β+ and subjects in blue amyloid-β− by florbetapir amyloid PET scan. Regression line is for amyloid-β+ subjects. Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) (2019). Published by Oxford University Press on behalf of the Guarantors of Brain.This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com Brain, awz090, https://doi.org/10.1093/brain/awz090 The content of this slide may be subject to copyright: please see the slide notes for details.

Figure 3 Freesurfer voxel-wise surface maps of mean flortaucipir SUVr values. For amyloid-β+ subjects at baseline ... Figure 3 Freesurfer voxel-wise surface maps of mean flortaucipir SUVr values. For amyloid-β+ subjects at baseline (top), and the mean voxel-wise change from baseline to 18 months (bottom). Subjects were stratified into four ‘quartiles’ (columns) based on their baseline MUBADA SUVr values to better evaluate change in flortaucipir PET distribution as a function of baseline tau burden. Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) (2019). Published by Oxford University Press on behalf of the Guarantors of Brain.This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com Brain, awz090, https://doi.org/10.1093/brain/awz090 The content of this slide may be subject to copyright: please see the slide notes for details.

Figure 4 Correlation of change from baseline flortaucipir PET MUBADA SUVr (A) or baseline flortaucipir PET MUBADA SUVr ... Figure 4 Correlation of change from baseline flortaucipir PET MUBADA SUVr (A) or baseline flortaucipir PET MUBADA SUVr (B) with change from baseline MMSE. Individual subjects are shown with symbols reflecting clinical diagnosis [cognitively normal (CN), MCI, Alzheimer’s disease (AD)]. Subjects shown in red were amyloid-β+ and subjects in blue amyloid-β− by florbetapir amyloid PET scan. Regression line is for amyloid-β+ subjects. Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) (2019). Published by Oxford University Press on behalf of the Guarantors of Brain.This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com Brain, awz090, https://doi.org/10.1093/brain/awz090 The content of this slide may be subject to copyright: please see the slide notes for details.